Japan’s Zeria To Start Phase III Trial For Functional Dyspepsia Therapy In Europe
This article was originally published in PharmAsia News
Tokyo-based Zeria Pharmaceutical announced European Phase II double-blind trial results for Z-338 (acotimiade), a functional dyspepsia therapy developed by the company. The trial was conducted in 76 facilities and enrolled 473 patients from eight countries. According to the company, the result showed acotimiade effective compared to placebo and there was no safety issue. Zeria has decided to start consultation with European Medicines Agency on a Phase III trial, and the company also is considering partnering with other companies to speed up the development process. Japanese major drug maker Astellas has licensed the drug's exclusive rights in the U.S., and the two companies are jointly conducting a Phase II trial. In Japan, Zeria and Astellas collaborate on an ongoing Phase III trial. In Japan, one in every four adults is found to have FD symptoms. (Click here for more - Japanese language
You may also be interested in...
US FDA declines to review the CCR5 antagonist for use in highly treatment-experienced HIV patients. Safety data from an ongoing study should be sufficient to address the agency’s concerns about the higher 700mg dose, CytoDyn management says, but FDA also has questions about the production of the self-injectable syringes.
Mallinckrodt's drug to treat hepatorenal syndrome met its primary endpoint of HRS reversal but FDA wants reassurance that this surrogate endpoint translates into a treatment effect on clinical outcomes. A greater incidence of respiratory failure in those receiving terlipressin "remains a significant safety concern," the agency says.
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.